CLL

BTK degrader NX-5948 has been granted Fast Track designation by the FDA to treat some adults with relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic lymphoma.

The top stories on chronic lymphocytic leukemia from 2023 included topics like BTK inhibitors, minimal residual disease status and approaches to care for various stages of the disease.

Managing a cancer support group isn't easy.

Brukinsa led to improved progression-free survival over Imbruvica in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, follow-up from the phase 3 ALPINE study showed.

Results from a four-year follow-up of a phase 3 trial determined that the combination of Imbruvica and Venclexta provided benefits for untreated patients with CLL.

The Food and Drug Administration approved Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who received two or more lines of therapy.

The Food and Drug Administration accepted a Priority Review for Breyanzi for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.

Recent years have brought more targeted agents to the frontline treatment for patients with chronic lymphocytic leukemia.

Autoimmune diseases in patients with CLL are separate from CLL, which calls for different treatments.

After receiving two cancer diagnoses, I became more vigilant about my health — especially during the COVID-19 pandemic.

Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed.

Never underestimate your value to a person who has just been diagnosed. Isn’t that what these blogs are all about anyway?

CURE looks back on some of the most important stories in the chronic lymphocytic leukemia space from 2023.

Patients with chronic lymphocytic leukemia treated with Imbruvica plus Venclexta demonstrated a healthy immune profile over time in addition to reduction in CLL disease burden.

Geoff Grubbs, who was diagnosed with chronic lymphocytic leukemia in 2009, has undergone five lines of treatment and participated in two clinical trials.

After being told, "You're not that bad" my whole life, I continued to hear that after being diagnosed with leukemia — which some called "the best" cancer to have.

CAR T-cell therapy positively benefitted patients with patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.

Patients 65 years and older treated with Venclexta, Imbruvica and Gazyva for CLL had similar rates of progression-free survival compared with those treated with Imbruvica and Gazyva.

Patients with inactive early-stage chronic lymphocytic leukemia may benefit from a wait-and-watch approach compared with immediate treatment with Imbruvica, findings from a phase 3 trial showed.

An ongoing trial is examining Calquence in older or frail patients with chronic lymphocytic leukemia — a group that is typically left out of clinical trials.

Days before I went on vacation, I learned that my blood cancer might have progressed to a more aggressive disease.

Before leaving on vacation, I had to make sure I had enough of my cancer medication to last me through the trip.

Findings from a study demonstrated that patients may develop hypertension, or high blood pressure, as a result of treatment with Imbruvica for CLL, although it may be quickly managed without drug-drug interactions.

An ultrasound revealed a solid mass in my breast that would need further follow-up.

A phase 1/1b trial will examine PRGN-3007 in patients with ROR1-positive hematologic and solid cancers.

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Personalized medicine means not only more powerful drugs for cancers, but also more precise mechanisms that target the specific consequence of mutations and other alterations that drive cancer cell growth, sparing normal cells.

Bruton tyrosine kinase inhibitors have changed the space for treating patients with CLL or SLL, with more on the way to potentially address drug resistance.